Title : A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Pub. Date : 2019 Dec

PMID : 31364164






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 These findings establish XMU-MP-3 as a novel inhibitor of BTK, which could serve as both a tool compound and a lead for further drug development in BTK relevant B-cell malignancies, especially those with the acquired ibrutinib-resistant C481S mutation. ibrutinib Bruton agammaglobulinemia tyrosine kinase Mus musculus